GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » Interest Coverage

Halozyme Therapeutics (FRA:RV7) Interest Coverage : 31.28 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Halozyme Therapeutics's Operating Income for the three months ended in Mar. 2025 was €131 Mil. Halozyme Therapeutics's Interest Expense for the three months ended in Mar. 2025 was €-4 Mil. Halozyme Therapeutics's interest coverage for the quarter that ended in Mar. 2025 was 31.28. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Halozyme Therapeutics's Interest Coverage or its related term are showing as below:

FRA:RV7' s Interest Coverage Range Over the Past 10 Years
Min: 3.68   Med: 16.89   Max: 36.66
Current: 32.99


FRA:RV7's Interest Coverage is ranked worse than
59.52% of 378 companies
in the Biotechnology industry
Industry Median: 125.165 vs FRA:RV7: 32.99

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Halozyme Therapeutics Interest Coverage Historical Data

The historical data trend for Halozyme Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Halozyme Therapeutics Interest Coverage Chart

Halozyme Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.08 36.66 15.79 17.99 30.48

Halozyme Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.20 25.91 36.07 38.65 31.28

Competitive Comparison of Halozyme Therapeutics's Interest Coverage

For the Biotechnology subindustry, Halozyme Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Interest Coverage falls into.


;
;

Halozyme Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Halozyme Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Halozyme Therapeutics's Interest Expense was €-17 Mil. Its Operating Income was €527 Mil. And its Long-Term Debt & Capital Lease Obligation was €1,438 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2024 )/Interest Expense (A: Dec. 2024 )
=-1*526.659/-17.281
=30.48

Halozyme Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Halozyme Therapeutics's Interest Expense was €-4 Mil. Its Operating Income was €131 Mil. And its Long-Term Debt & Capital Lease Obligation was €1,394 Mil.

Interest Coverage=-1* Operating Income (Q: Mar. 2025 )/Interest Expense (Q: Mar. 2025 )
=-1*130.92/-4.186
=31.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Halozyme Therapeutics  (FRA:RV7) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Halozyme Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics Business Description

Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics Headlines

No Headlines